Published in Oncotarget on May 03, 2016
PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer. Oncotarget (2017) 0.75
Selective glucocorticoid receptor modulators (SGRMs) delay castrate-resistant prostate cancer growth. Mol Cancer Ther (2017) 0.75
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
LNCaP model of human prostatic carcinoma. Cancer Res (1983) 7.23
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res (2012) 5.50
Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res (2001) 4.12
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell (2013) 3.59
Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife (2013) 3.49
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science (2015) 3.48
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med (1997) 3.46
Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res (2002) 3.25
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol (2014) 3.10
Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev (2007) 2.96
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov (2013) 2.87
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov (2013) 2.52
Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A (2008) 2.47
Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res (2000) 2.44
Alternatively spliced androgen receptor variants. Endocr Relat Cancer (2011) 2.41
Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. J Urol (2005) 2.36
Linking beta-catenin to androgen-signaling pathway. J Biol Chem (2002) 2.27
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res (1996) 2.18
Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res (2006) 2.02
The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell (2012) 1.98
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98
Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer (2007) 1.94
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene (2013) 1.67
Bioinformatics applications for pathway analysis of microarray data. Curr Opin Biotechnol (2008) 1.59
Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol (1998) 1.57
Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. Oncogene (2002) 1.51
Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis. Oncogene (2003) 1.32
The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol (2008) 1.21
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer (2014) 1.14
Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer (2002) 1.13
TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene (2002) 1.12
The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol (1994) 1.09
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 1.04
Labeling nuclear DNA using DAPI. Cold Spring Harb Protoc (2011) 1.02
Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One (2013) 1.00
Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells. Endocrinology (1997) 0.97
The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int J Cancer (2014) 0.96
Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res (2000) 0.93
The identification of novel targets of miR-16 and characterization of their biological functions in cancer cells. Mol Cancer (2013) 0.92
Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. Prostate (2003) 0.90
Labeling cytoskeletal F-actin with rhodamine phalloidin or fluorescein phalloidin for imaging. Cold Spring Harb Protoc (2010) 0.90
Metallothioneins and resistance to cisplatin and radiation in prostate cancer. Urology (2006) 0.87
Molecular analysis of CD133-positive circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Sci (2015) 0.84
Corticosteroids and prostate cancer: friend or foe? Eur Urol (2014) 0.75